PremiumRatingsCautious Hold on Adaptimmune Therapeutics Amid Strategic Developments and Liquidity Concerns Promising Growth Prospects and Strategic Advancements Drive Buy Rating for Adaptimmune Therapeutics Adaptimmune price target lowered to $1 from $1.50 at Wells Fargo PremiumThe FlyAdaptimmune downgraded to Hold from Buy at JonesResearch Adaptimmune Therapeutics: Hold Rating Amid Financial Uncertainties and Strategic Challenges Adaptimmune price target lowered to $3 from $3.50 at H.C. Wainwright PremiumThe FlyAdaptimmune price target lowered to $1.50 from $2 at Wells Fargo Adaptimmune’s Strategic Moves in Cancer Therapy Adaptimmune Therapeutics Reports Q4 2024 Business Update